Finally, the Commission notes that the Final Commitments remove serious doubts
regarding Mars gaining access to competitively sensitive information in the downstream market (for example, on prices, quantities, product characteristics, etc.) of its upstream competitors. The Final Commitments ensure that VetFamily will be operated, and commercial terms will be negotiated, by an independent entity and hence Mars will not obtain access to the commercial terms that its upstream competitors offer to VetFamily clinics, Thus, Mars' upstream competitors will be able to offer commercial terms to non-AniCura clinics, which comprise around three quarters of the downstream market in each Sweden and Denmark, without making them known to Mars. At the same time, the terms offered by Mars' upstream competitors to AniCura clinics and to VetFamily clinics will not necessarily be the same post-Transaction, thus preserving uncertainty and conditions for competition.